Yubo International Biotech Limited
YBGJ · OTC
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.41 | -0.27 | 0.78 |
| FCF Yield | -32.22% | 0.25% | -3.22% | 0.01% |
| EV / EBITDA | -2.57 | -10.23 | -34.13 | -74.47 |
| Quality | ||||
| ROIC | 56.24% | -535.25% | -60.19% | -48.00% |
| Gross Margin | -6,030.98% | 50.49% | 65.95% | 91.56% |
| Cash Conversion Ratio | 0.75 | -0.06 | 0.66 | -0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -85.92% | -57.45% | – | – |
| Free Cash Flow Growth | 0.00% | 101.79% | -43,671.83% | 111.37% |
| Safety | ||||
| Net Debt / EBITDA | -0.26 | -0.66 | -1.75 | 1.53 |
| Interest Coverage | 0.00 | -5,262.98 | -0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 5.76 | 0.16 | 2.58 | 1.70 |
| Cash Conversion Cycle | 44,814.11 | -400.64 | 68.05 | 7.76 |